Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of follitropin ${\beta}$ administered by a pen device with follitropin ${\beta}$ administered by a conventional syringe in patients undergoing IVF-ET

  • Kang, Hyuk-Jae (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Chung-Hoon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicinel) ;
  • Ahn, Jun-Woo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Hyang-Ah (Department of Obstetrics and Gynecology, Kangwon National University Hospital, Kangwon National University School of Medicine) ;
  • Kim, Sung-Hoon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chae, Hee-Dong (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kang, Byung-Moon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2010.09.05
  • Accepted : 2010.11.11
  • Published : 2011.03.02
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To compare the effectiveness and convenience of a pen device for the self-administration of follitropin ${\beta}$ with a conventional syringe delivering follitropin ${\beta}$ solution in patients undergoing IVF-ET. Methods: GnRH agonist long protocol was used for controlled ovarian stimulation (COS) in all subjects. A total of 100 patients were randomized into the pen device group or the conventional syringe group on the first day of COS. Local tolerance reactions were assessed within 5 minutes, at 1 hour and at 3 hours after each injection. On the day of hCG injection, patients were asked to rate their overall pain and convenience experienced with self-injection on a visual anlaogue scale (VAS). Results: There were no differences in patients' characteristics between the two groups. The duration of COS was significantly shorter in the pen device group than in the conventional syringe group. Patients included in the pen device group needed a significantly smaller amount of follitropin ${\beta}$. However, no differences between the two groups were found in IVF results and pregnancy outcome. The incidence of local pain within 5 minutes, at 1 hour and at 3 hours after the injection was significantly lower in the pen device group. VAS scores indicated that injections using the pen device were significantly less painful and more convenient. Conclusion: The pen device for self-administration of follitropin ${\beta}$ is less painful, safer and more convenient for the patients, and can be more effective because of the shorter duration and smaller dose of follitropin ${\beta}$ when compared with the conventional syringe.

Keywords

References

  1. Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod 1994;9:424-30. https://doi.org/10.1093/oxfordjournals.humrep.a138522
  2. Wikland M, Borg J, Hamberger L, Svalander P. Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod 1994;9:1430-6. https://doi.org/10.1093/oxfordjournals.humrep.a138724
  3. Kadiri A, Chraibi A, Marouan F, Ababou MR, el Guermai N, Wadjinny A, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract 1998;41:15-23. https://doi.org/10.1016/S0168-8227(98)00055-2
  4. Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med 1999;106:57-8.
  5. Robertson KE, Glazer NB, Campbell RK. The latest developments in insulin injection devices. Diabetes Educ 2000;26:135-8. https://doi.org/10.1177/014572170002600114
  6. Bohannon NJ, Ohannesian JP, Burdan AL, Holcombe JH, Zagar A. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther 2000;22:1049-67. https://doi.org/10.1016/S0149-2918(00)80084-3
  7. Voortman G, van de Post J, Schoemaker RC, van Gerven JM. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe. Hum Reprod 1999;14:1698-702. https://doi.org/10.1093/humrep/14.7.1698
  8. Rama Raju GA, Suryanarayana K, Jaya Prakash G, Murali Krishna K. Comparison of follitropin-beta administered by a pen device with conventional syringe in an ART programme: a retrospective study. J Clin Pharm Ther 2008;33:401-7. https://doi.org/10.1111/j.1365-2710.2008.00931.x
  9. Craenmehr E, Bontje PM, Hoomans E, Voortman G, Mannaerts BM. Follitropin-beta administered by pen device has superior local tolerance compared with follitropin-alpha administered by conventional syringe. Reprod Biomed Online 2001;3:185-9. https://doi.org/10.1016/S1472-6483(10)62033-0

Cited by

  1. Human factors engineering and design validation for the redesigned follitropin alfa pen injection device vol.12, pp.5, 2015, https://doi.org/10.1517/17425247.2015.1033395